# Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM

> **NCT01804842** · PHASE1,PHASE2 · COMPLETED · sponsor: **Elcelyx Therapeutics, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Met DR

## Key facts

- **NCT ID:** NCT01804842
- **Lead sponsor:** Elcelyx Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2016-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01804842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01804842, "Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01804842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*